ATXI logo

Avenue Therapeutics, Inc. Stock Price

OTCPK:ATXI Community·US$1.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

ATXI Share Price Performance

US$0.32
0.10 (48.77%)
US$0.32
0.10 (48.77%)
Price US$0.32

ATXI Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward

Avenue Therapeutics, Inc. Key Details

US$1.4m

Revenue

US$0

Cost of Revenue

US$1.4m

Gross Profit

US$3.2m

Other Expenses

-US$1.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.53
100.00%
-124.79%
0%
View Full Analysis

About ATXI

Founded
2015
Employees
1
CEO
Alexandra MacLean
WebsiteView website
avenuetx.com

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.

Recent ATXI News & Updates

Recent updates

No updates